Autolus Therapeutics (NASDAQ:AUTL) Sees Large Volume Increase – Time to Buy?

Autolus Therapeutics plc (NASDAQ:AUTL) saw strong trading volume on Wednesday . 2,674,034 shares changed hands during mid-day trading, an increase of 93% from the previous session’s volume of 1,386,659 shares.The stock last traded at $3.42 and had previously closed at $3.38.

Autolus Therapeutics Stock Performance

The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $3.99 and a 200 day moving average price of $4.02. The firm has a market cap of $949.96 million, a PE ratio of -2.91 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities research analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $43,000. Bayesian Capital Management LP purchased a new position in shares of Autolus Therapeutics in the 1st quarter valued at $100,000. Daiwa Securities Group Inc. raised its stake in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after acquiring an additional 15,293 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in Autolus Therapeutics in the first quarter valued at $108,000. Finally, SG Americas Securities LLC acquired a new position in Autolus Therapeutics in the first quarter valued at $127,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.